NRC FORM 591M PART 1
(10-2003) 10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Marquette General Health System **580 West College** **Marquette, MI 49855-2705** REPORT NUMBER(S)	**U.S. Nuclear Regulatory Commission** **Region III** **2443 Warrenville Road** **Suite 210** **Lisle, Illinois 60532-4351**

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-18133	**21-05432-04**	July 28, 2009

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☑ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	**Robert P. Hays**		7/28/09

RP Bloom

NRC FORM 591M PART 3
(10-2003) 10 CFR 2.201

Docket File Information

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
Marquette General Health System REPORT NUMBER(S) 2009-001	Region III 2443 Warrenville Road, Suite 210 Lisle, IL 60532

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
03018133	21-05432-04	July 28, 2009

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87132 (12/06/05)	03.01-03.07

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02240	2	Shan Marlette, RSO	906-225-3777

[X] Main Office Inspection — Next Inspection Date: July 2011

[ ] Field Office

[ ] Temporary Job Site Inspection

PROGRAM SCOPE

The licensee was a medical institution located in Marquette, Michigan, with authorization by the license for diagnostic and therapeutic nuclear medicine procedures, low dose brachytherapy procedures; GliaSite treatment procedures; and SIR-Spheres for liver cancer therapy as specified on the license.

The "south" nuclear medicine department was staffed by three full-time nuclear medicine technologists (NMTs) who conduct an average of 4-8 patient studies per day. The "north" nuclear medicine department is used only for cardiac studies and was not inspected during this inspection. The licensee periodically receives a generator as available from the vendor.

The licensee's brachytherapy program involved cesium-137 implants and patient cases averaged 3-4 per year. SIR Spheres are used for liver cancer therapy and patient cases averaged one per month. No GliaSite® procedures have been performed due to Iotrex solution being discontinued and unavailable by the vendor.

Performance Observations

During the inspection, the licensee's available staff demonstrated/discussed: (1) generator elution, moly tests, dosage prep, syringe labeling, and safe use; (2) package check-in and return procedures; (3) wipe test counting (4) survey instruments and required surveys; (5) dosimetry; (6) written directives and treatment plans; (7) security and storage of licensed material; (8) radiation safety program audit results; (9) SIR Sphere procedures (10) sealed source inventory and leak tests; (11) 10 CFR 30.41 transfers as waste disposals; and (12) any minor contamination events. (none).